Dogwood Therapeutics, Inc.

Our Company is a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathy. Following a combination, the company became the sole owner of Pharmagesic (Holdings) Inc. and its wholly owned subsidiary, Wex Pharmaceuticals, Inc. Wex Pharmaceuticals, Inc. wholly owns IWT Bio, Inc., Wex Medical Corporation, and Wex Medical Limited. The company's pipeline is focused on treating chronic neuropathic pain and neuropathy. Its Halneuron® Na v 1.7 modulation program is intended to treat chronic and acute pain disorders. The recently licensed SP16 program is centered on a cell signaling molecule that has shown early promise in treating neuropathy and nerve damage. The Halneuron® program is a proprietary non-opioid Na v 1.7 analgesic program centered on voltage-gated sodium channel modulation. SP16 is the focus of a planned Phase 1b study that is fully funded through a research grant supplied by the National Cancer Institute, with patient enrollment projected to start in mid-2026. The lead product candidate, Halneuron®, is in late-stage clinical development for the treatment of chemotherapy-induced neuropathic pain ("CINP"). The active pharmaceutical ingredient is highly purified Tetrodotoxin ("TTX"), a potent sodium channel modulator. Halneuron® works as an analgesic by modulating the activity of Na v 1.7, a key sodium channel involved in pain signal transmission.